ABCL AbCellera Biologics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABCL

Price (delayed)

$10.97

Market cap

$3.36B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.54

Enterprise value

$3.35B

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 36

AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s platform integrates technology, data science, infrastructure, and interdisciplinary teams ...

Highlights
AbCellera Biologics's debt has decreased by 5% YoY and by 3.2% from the previous quarter
The gross profit has soared by 101% YoY but it has contracted by 16% from the previous quarter
The company's revenue has surged by 101% YoY but it fell by 16% QoQ
AbCellera Biologics's net income has decreased by 14% from the previous quarter
ABCL's EPS is down by 13% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.abcellera.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ABCL

ABCL stock price

How has the AbCellera Biologics stock price performed over time
Intraday
5.94%
1 week
67.99%
1 month
68.25%
1 year
139.52%
YTD
220.76%
QTD
39.75%

Financial performance

How have AbCellera Biologics's revenue and profit performed over time
Revenue
$66.17M
Gross profit
$66.17M
Operating income
-$225.16M
Net income
-$164.66M
Gross margin
100%
Net margin
-248.8%
The gross profit has soared by 101% YoY but it has contracted by 16% from the previous quarter
The company's revenue has surged by 101% YoY but it fell by 16% QoQ
AbCellera Biologics's operating margin has surged by 60% YoY but it has decreased by 27% QoQ
AbCellera Biologics's net margin has soared by 51% YoY but it has decreased by 37% from the previous quarter

Price vs fundamentals

How does ABCL's price correlate with its fundamentals

Growth

What is AbCellera Biologics's growth rate over time

Valuation

What is AbCellera Biologics stock price valuation
P/E
N/A
P/B
3.74
P/S
50.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
50.6
ABCL's EPS is down by 13% from the previous quarter
ABCL's P/B is 134% above its last 4 quarters average of 1.6 and 108% above its 5-year quarterly average of 1.8
The equity has declined by 11% year-on-year and by 4.5% since the previous quarter
The P/S is 140% more than the 5-year quarterly average of 21.1 and 92% more than the last 4 quarters average of 26.4
The company's revenue has surged by 101% YoY but it fell by 16% QoQ

Efficiency

How efficient is AbCellera Biologics business performance
ABCL's ROS has soared by 53% YoY but it is down by 28% from the previous quarter
AbCellera Biologics's ROE has decreased by 17% from the previous quarter and by 10% YoY
The ROA has contracted by 17% from the previous quarter and by 3.3% YoY
The company's return on invested capital rose by 11% YoY but it fell by 10% QoQ

Dividends

What is ABCL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABCL.

Financial health

How did AbCellera Biologics financials performed over time
The company's quick ratio rose by 18% YoY but it fell by 8% QoQ
ABCL's current ratio is up by 15% YoY but it is down by 9% QoQ
AbCellera Biologics's debt is 85% less than its equity
The equity has declined by 11% year-on-year and by 4.5% since the previous quarter
The company's debt to equity rose by 7% QoQ and by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.